Cancer Research

Cancer Research
  • Pininvest Analysis

Our selection for cancer research attempts to mirror some of the transformative forces at play in biotechnology

Clinical stage research remains a significant market segment as large pharmaceutical enterprises see value in farming out some of their research – read our theme dedicated to clinical companies (to be published soon)

But, conversely, large biopharma companies, often highly valued by the market because of their growth expectations, may consider integration of former or current partner firms to diversify their drug pipeline – possibly guaranteeing a significant part of future earnings of future drugs to former owners, to clinch a deal …

Read our note

Cancer Research • Updated:

Name Ticker Exchange Sector Industry Currency Cur.Price Mkt.Cap Perf. Vol. Risk Contrib. MDD
 
bluebird bio, Inc. BLUE NASDAQ Health Care Biopharmaceuticals USD 45.87 3.0 B -42.8% 68%   9% -59%
Bristol-Myers Squibb BMY NYSE Health Care Drug Manufacturers - Diversified USD 62.41 141 B 11.8% 29%   4% -31%
Geron GERN NASDAQ Health Care Drug Manufacturers - Diversified USD 1.84 571 M 28.7% 69%   8% -42%
Incyte Corporation INCY NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 85.42 19 B -9.6% 42%   5% -34%
Inovio Pharmaceuticals INO NASDAQ Health Care Biopharmaceuticals USD 12.42 2.1 B 394.8% 173%   18% -73%
Lumos Pharma LUMO NASDAQ Health Care Biopharmaceuticals USD 15.51 129 M 12.3% 87%   8% -75%
Merrimack Pharmaceuticals, Inc. MACK NASDAQ Health Care Biopharmaceuticals USD 4.08 55 M 22.1% 61%   4% -53%
NantKwest, Inc. NK NASDAQ Health Care Biopharmaceuticals USD 9.70 1.0 B 542.4% 146%   21% -59%
Seattle Genetics Inc. SGEN NASDAQ Health Care Biopharmaceuticals USD 177.41 31 B 51.5% 47%   7% -22%
Siemens Healthineers SMMNY OTC Health Care Specialized Medical Devices USD 22.89 - -2.6% 35%   4% -30%
ZIOPHARM Oncology ZIOP NASDAQ Health Care Biopharmaceuticals USD 2.85 610 M -44.2% 80%   12% -64%